Establishment Labs Announces Participation in Two Upcoming Investment Conferences
10 Novembro 2023 - 10:00AM
Business Wire
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global
medical technology company dedicated to improving women’s health
and wellness, principally in breast aesthetics and reconstruction,
today announced its participation in two upcoming investment
conferences.
Juan José Chacón-Quirós, Chief Executive Officer and Founder,
and Raj Denhoy, Chief Financial Officer, will participate in the
2023 Jefferies London Healthcare Conference held November 14-16,
2023. Mr. Chacón-Quirós and Mr. Denhoy are scheduled to speak in
person to conference attendees on Tuesday, November 14 at 4:30-4:55
PM GMT.
Mr. Denhoy will also participate in the Stephens Annual
Investment Conference, being held on November 14-16, 2023. Mr.
Denhoy is scheduled to speak in person to conference attendees on
Thursday, November 16, 2023, at 10:00 AM CT.
Live webcasts of the presentations will be available to all
interested parties on the Establishment Labs investor relations
website at https://investors.establishmentlabs.com/. Archived
versions of the webcasts will be available on the same website
following the completion of the events.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology
company dedicated to improving women’s health and wellness through
the power of science, engineering, and technology. The Company
offers a portfolio of Femtech solutions for breast health, breast
aesthetics and breast reconstruction. The over three million
Motiva® devices Establishment Labs has delivered to plastic and
reconstructive surgeons since 2010 have created a new standard for
safety and patient satisfaction in the over 85 countries in which
they are available. The Motiva Flora® tissue expander is used to
improve outcomes in breast reconstruction following breast cancer
and it is the only regulatory-approved expander in the world with
an integrated port using radio-frequency technology that is MRI
conditional. Mia Femtech™, Establishment Lab’s unique minimally
invasive experience for breast harmony, is the Company’s most
recent breakthrough innovation. These solutions are supported by
over 200 patent applications in 25 separate patent families
worldwide and over 50 scientific studies and publications in peer
reviewed journals. Establishment Labs manufactures at two
facilities in Costa Rica compliant with all applicable regulatory
standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP
program. In 2018, the Company received an investigational device
exemption (IDE) from the FDA for Motiva Implants® and began a
clinical trial to support regulatory approval in the United States.
Please visit our website for additional information at
www.establishmentlabs.com.
Establishment Labs' Motiva silicone gel-filled implants are
currently not approved for commercial distribution in the United
States. The Company’s implants are undergoing PMA clinical
investigation pursuant to U.S. FDA regulations for investigational
medical devices.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231109182253/en/
Investor/Media Contact: Raj Denhoy 415-828-1044
rdenhoy@establishmentlabs.com
Establishment Labs (NASDAQ:ESTA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Establishment Labs (NASDAQ:ESTA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024